Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

Also called NCT02317458

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Celyad Oncology SA (from the registry)
Registry
  • NCT NCT02317458
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
Not reported
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02317458. Randomized; quadruple masking; primary purpose treatment. Start 2017-06 (registry gives no type); primary completion 2020-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial - THE CHART-2 TRIAL
Acronym
CHART-2
Condition
Heart Failure
Intervention (Biological)
Experimental
Intervention (Biological)
Sham comparator
Lead sponsor
Celyad Oncology SA (class: industry)

Record details

Record id
cardio:ct-nct02317458
Content hash
0d84ff2bb9425b83535512ef7d457139fcadd00057cc3c2311a73c04866eddef